Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

SOPHiA GENETICS expands ovarian cancer testing in Spain

Published 07/02/2024, 12:04
Updated 07/02/2024, 12:04
© Reuters

BOSTON, ROLLE, Switzerland, and MADRID - SOPHiA GENETICS (NASDAQ: SOPH), in collaboration with AstraZeneca (NASDAQ:AZN) Spain, announced today an expansion of their program to enhance access to homologous recombination deficiency (HRD) testing for ovarian cancer across Spain. This initiative aims to support molecular diagnosis and accelerate precision treatment planning for patients.

The partnership, which began in 2022, initially enabled five Spanish laboratories to implement HRD testing, leading to the analysis of over 4,000 samples. With this expansion, SOPHiA GENETICS becomes the preferred partner for HRD testing deployment in Spain, potentially increasing the number of labs with in-house HRD detection capabilities.

HRD is a key biomarker in ovarian cancer, affecting approximately 50% of new diagnoses. It indicates a tumor's response to certain treatments, making its detection crucial for effective patient care. The collaboration seeks to leverage the SOPHiA DDM™ Platform to improve diagnostics and data-driven treatment strategies.

AstraZeneca Spain, part of AstraZeneca (LSE/STO/NASDAQ: AZN), a biopharmaceutical company, is committed to chronicling cancer and advancing personalized medicine. Marta Moreno, director of Corporate Affairs and Market Access of AstraZeneca Spain, emphasized the importance of biomarker studies in providing personalized treatments with a higher guarantee of effectiveness.

Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS, highlighted the significance of local testing for HRD in Spain, which contributes to global data on HRD and advances treatment options for ovarian cancer.

The expansion of this testing program is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.